StockData

Aclarion vs BioRestorative Therapies

ACON and BRTX side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ACON and BRTX compare

BioRestorative Therapies is the larger company, worth 8.5 times as much as Aclarion ($39.7M against $4.7M).

Aclarion grew revenue faster over the last twelve months (46.0% versus −8.5% for BioRestorative Therapies).

BioRestorative Therapies keeps more of each dollar of sales as profit, with a net margin of −3090% compared with −10260% at Aclarion.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricACONBRTX
Size and price
Market cap$4.7M$39.7M
Share price$1.63$1.56
Change, 1 year−77.5%−94.3%
Change, 5 years–−98.9%
Beta (5Y)0.771.08
Employees1114
StockData Score
Total score88
Valuation score1 (better)0
Growth score22
Performance score01 (better)
Health score55
Dividend score00
Valuation
P/S47.7× (better)111×
P/B0.3× (better)13.1×
Growth
Revenue growth (TTM)46.0% (better)−8.5%
Revenue growth, 5Y average–36.1%
Profitability
Gross margin29.1%92.1% (better)
Operating margin−10789%−3975% (better)
Net margin−10260%−3090% (better)
Return on equity−74.1% (better)−241%
Return on invested capital−959%–
Financial health
Debt / equity0.000.00
Current ratio14.17 (better)2.35
Altman Z-score−4.34 (better)−46.62
Piotroski F-score6 (better)2
Dividends and buybacks
Buyback yield−33.4%–
Shareholder yield−33.4%0.00% (better)
Ownership
Held by institutions9.0%0.52%
Held by insiders16.4%9.6%
Insider net buying, 12 months$177K–
Short interest, % of float–0.16%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.